2 January 2020 - Aerie Pharmaceuticals today announced that the EMA has accepted for review the marketing authorisation application for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%.
Roclanda is currently marketed as Rocklatan in the United States, where it is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
An opinion from the EMA’s Committee for Medicinal Products for Human Use on the application for Roclanda is expected in late 2020.